BioStock: Cereno reveals promising data for preclinical CVD candidate

In June, Cereno Scientific presented preclinical data regarding the recently nominated candidate drug CS585 at the EHA Congress. The data indicate that CS585 is able to prevent clotting without increasing the risk of bleeding, thereby being a potential breakthrough treatment for thrombosis. The company has put together a video presentation explaining the results and why they indicate that CS585 has the potential to truly transform CVD treatment.

Read the article at biostock.se:

https://www.biostock.se/en/2022/09/cereno-presenterar-lovande-data-for-preklinisk-cvd-kandidat/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/